The Relationship of Visfatin Levels with Insulin Resistance and Left Ventricular Hypertrophy in Peritoneal Dialysis Patients

被引:4
作者
Karakan, Sebnem [1 ]
Sezer, Siren [1 ]
Acar, F. Nurhan Ozdemir [2 ]
Haberal, Mehmet [3 ]
机构
[1] Baskent Univ, Dept Nephrol, TR-06490 Ankara, Turkey
[2] Baskent Univ, Dept Nephrol, Istanbul, Turkey
[3] Baskent Univ, Dept Gen Surg, TR-06490 Ankara, Turkey
关键词
peritoneal dialysis; insulin resistance; visfatin; COLONY-ENHANCING FACTOR; TYPE-2; DIABETES-MELLITUS; STAGE RENAL-DISEASE; PLASMA VISFATIN; ADIPOSE-TISSUE; METABOLIC SYNDROME; GLUCOSE EXPOSURE; CELL-FUNCTION; INFLAMMATION; OBESITY;
D O I
10.3109/0886022X.2012.676493
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/objectives: Cardiovascular abnormalities are common in patients with chronic kidney disease. Visfatin influences lipid metabolism, insulin sensitivity, and cardiovascular health. The aim of this study was to explore the relation of serum visfatin to cardiovascular risk factors in nondiabetic peritoneal dialysis (PD) patients. Patients and methods: Eighty-seven nondiabetic patients (mean age 48 +/- 15 years, 39 males) under PD were enrolled. Weight, anthropometric measurements, blood pressure, biochemical parameters, and insulin resistance (homeostatic model assessment-insulin resistance-HOMA-IR) were measured. Visfatin was measured and left ventricular mass index (LVMI) was calculated by echocardiography. Results: LVMI was correlated with body mass index (BMI; r = 0.47, p = 0.01), systolic blood pressure (SBP; r = 0.62, p = 0.04), and serum visfatin levels (r = 0.49, p = 0.03). According to HOMA-IR levels patients were grouped as insulin-resistant (IR) (HOMA-IR >= 2.0, n = 35) and noninsulin-resistant (non-IR) (HOMA-IR <2.0, n = 52) groups. The IR group had longer PD duration and higher BMI, total cholesterol, uric acid, and serum visfatin levels (p < 0.05). The study patients were divided into three groups according to their serum visfatin levels. Group 1 (<= 34 ng/mL, n = 22) was considered as the lowest tertile of low visfatin and group 2 (35-42 ng/mL, n = 43) and group 3 (>= 43 ng/mL, n = 22) in the upper tertile. Considering the visfatin groups, group 3 patients had significantly higher BMI (p = 0.00), total cholesterol (p = 0.03), C-reactive protein (CRP) (p = 0.03), HOMA-IR (p = 0.03), and LVMI (p = 0.02). In regression analysis, SBP (beta = 0.19, p < 0.05) and serum visfatin levels (beta = 0.74, p < 0.05) were independent variables affecting LVMI. Conclusion: Serum visfatin might be a sensitive marker than HOMA-IR evaluations for cardiac performance in nondiabetic PD patients.
引用
收藏
页码:732 / 737
页数:6
相关论文
共 41 条
[1]   Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis [J].
Adya, Raghu ;
Tan, Bee K. ;
Punn, Anu ;
Chen, Jing ;
Randeva, Harpal S. .
CARDIOVASCULAR RESEARCH, 2008, 78 (02) :356-365
[2]   Circulating levels of Visfatin/Pre-B-Cell colony-enhancing factor 1 in relation to genotype,GFR, body composition, and survival in patients with CKD [J].
Axelsson, Jonas ;
Witasp, Anna ;
Carrero, Juan Jesus ;
Qureshi, Abdul R. ;
Suliman, Mohamed E. ;
Heimbuerger, Olof ;
Barany, Peter ;
Lindholm, Bengt ;
Alvestrand, Anders ;
Schalling, Martin ;
Nordfors, Louise ;
Stenvinkel, Peter .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (02) :237-244
[3]   Plasma visfatin concentrations and fat depot-specific mRNA expression in humans [J].
Berndt, J ;
Klöting, N ;
Kralisch, S ;
Kovacs, P ;
Fasshauer, M ;
Schön, MR ;
Stumvoll, M ;
Blüher, M .
DIABETES, 2005, 54 (10) :2911-2916
[4]   Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus [J].
Chen, MP ;
Chung, FM ;
Chang, DM ;
Tsai, JCR ;
Huang, HF ;
Shin, SJ ;
Lee, YJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) :295-299
[5]  
Cottone S, 2007, CLIN NEPHROL, V67, P209
[6]   Metabolic syndrome - A comprehensive perspective based on interactions between obesity, diabetes, and inflammation [J].
Dandona, P ;
Aljada, A ;
Chaudhuri, A ;
Mohanty, P ;
Garg, R .
CIRCULATION, 2005, 111 (11) :1448-1454
[7]  
Davies SJ, 2001, J AM SOC NEPHROL, V12, P1046, DOI 10.1681/ASN.V1251046
[8]   INSULIN RESISTANCE IN UREMIA [J].
DEFRONZO, RA ;
ALVESTRAND, A ;
SMITH, D ;
HENDLER, R ;
HENDLER, E ;
WAHREN, J .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 67 (02) :563-568
[9]  
DESANTO NG, 1979, INT J ARTIF ORGANS, V2, P193
[10]   ECHOCARDIOGRAPHIC ASSESSMENT OF LEFT-VENTRICULAR HYPERTROPHY - COMPARISON TO NECROPSY FINDINGS [J].
DEVEREUX, RB ;
ALONSO, DR ;
LUTAS, EM ;
GOTTLIEB, GJ ;
CAMPO, E ;
SACHS, I ;
REICHEK, N .
AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (06) :450-458